Castle Biosciences Quarterly Income Statements Chart
Quarterly
|
Annual
Castle Biosciences Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| net revenues | 86,188,000 | 87,988,000 | 86,311,000 | 85,782,000 | 87,002,000 | 72,974,000 | 66,120,000 | 61,493,000 | 50,138,000 | 42,037,000 | 38,338,000 | 37,011,000 | 34,838,000 | 26,852,000 | 25,039,000 | 23,475,000 | 22,758,000 | 22,813,000 | 17,299,000 | 15,217,000 | 12,715,000 | 17,418,000 | 17,634,553 | 14,774,891 | 10,738,569 |
| yoy | -0.94% | 20.57% | 30.54% | 39.50% | 73.53% | 73.59% | 72.47% | 66.15% | 43.92% | 56.55% | 53.11% | 57.66% | 53.08% | 17.70% | 44.74% | 54.27% | 78.99% | 30.97% | -1.90% | 2.99% | 18.40% | ||||
| qoq | -2.05% | 1.94% | 0.62% | -1.40% | 19.22% | 10.37% | 7.52% | 22.65% | 19.27% | 9.65% | 3.59% | 6.24% | 29.74% | 7.24% | 6.66% | 3.15% | -0.24% | 31.87% | 13.68% | 19.68% | -27.00% | -1.23% | 19.35% | 37.59% | |
| operating expenses | |||||||||||||||||||||||||
| cost of sales | 17,626,000 | 16,383,000 | 16,183,000 | 15,609,000 | 14,519,000 | 13,894,000 | 12,423,000 | 11,319,000 | 11,058,000 | 10,182,000 | 9,520,000 | 8,859,000 | 7,686,000 | 5,944,000 | 4,597,000 | 4,500,000 | 3,697,000 | 3,028,000 | 2,673,000 | 2,475,000 | 2,146,000 | 2,391,000 | 2,010,536 | 1,708,722 | 1,992,784 |
| gross profit | 68,562,000 | 71,605,000 | 70,128,000 | 70,173,000 | 72,483,000 | 59,080,000 | 53,697,000 | 50,174,000 | 39,080,000 | 31,855,000 | 28,818,000 | 28,152,000 | 27,152,000 | 20,908,000 | 20,442,000 | 18,975,000 | 19,061,000 | 19,785,000 | 14,626,000 | 12,742,000 | 10,569,000 | 15,027,000 | 15,624,017 | 13,066,169 | 8,745,785 |
| yoy | -5.41% | 21.20% | 30.60% | 39.86% | 85.47% | 85.47% | 86.33% | 78.23% | 43.93% | 52.36% | 40.97% | 48.36% | 42.45% | 5.68% | 39.76% | 48.92% | 80.35% | 31.66% | -6.39% | -2.48% | 20.85% | ||||
| qoq | -4.25% | 2.11% | -0.06% | -3.19% | 22.69% | 10.02% | 7.02% | 28.39% | 22.68% | 10.54% | 2.37% | 3.68% | 29.86% | 2.28% | 7.73% | -0.45% | -3.66% | 35.27% | 14.79% | 20.56% | -29.67% | -3.82% | 19.58% | 49.40% | |
| gross margin % | 79.55% | 81.38% | 81.25% | 81.80% | 83.31% | 80.96% | 81.21% | 81.59% | 77.94% | 75.78% | 75.17% | 76.06% | 77.94% | 77.86% | 81.64% | 80.83% | 83.76% | 86.73% | 84.55% | 83.74% | 83.12% | 86.27% | 88.60% | 88.43% | 81.44% |
| research and development | 12,787,000 | 12,588,000 | 11,773,000 | 12,323,000 | 14,136,000 | 13,809,000 | 12,994,000 | 12,923,000 | 13,308,000 | 14,393,000 | 11,309,000 | 10,907,000 | 11,926,000 | 10,761,000 | 9,445,000 | 7,500,000 | 6,793,000 | 5,908,000 | 4,581,000 | 3,058,000 | 2,704,000 | 2,913,000 | 3,158,946 | 1,514,966 | 1,317,237 |
| selling, general and administrative | 58,065,000 | 58,620,000 | 49,965,000 | 50,499,000 | 51,088,000 | 48,495,000 | 44,090,000 | 44,619,000 | 44,681,000 | 46,762,000 | 38,426,000 | 36,626,000 | 37,498,000 | 30,453,000 | 25,160,000 | 22,595,000 | 20,822,000 | 18,161,000 | 14,959,000 | 11,703,000 | 10,392,000 | 11,078,000 | 9,852,469 | 7,121,982 | 6,820,927 |
| amortization of acquired intangible assets | 1,961,000 | 28,325,000 | 4,340,000 | 2,272,000 | 2,247,000 | 2,247,000 | 2,271,000 | 2,272,000 | 2,248,000 | 2,222,000 | 2,215,000 | 2,306,000 | 2,097,000 | 1,648,000 | |||||||||||
| total operating expenses | 90,439,000 | 115,916,000 | 82,261,000 | 80,703,000 | 81,990,000 | 78,445,000 | 71,778,000 | 71,133,000 | 71,295,000 | 73,559,000 | 61,170,000 | 58,547,000 | 38,809,000 | 51,368,000 | 40,210,000 | 35,289,000 | 31,568,000 | 24,069,000 | 17,658,000 | 16,643,000 | 11,214,000 | 13,991,000 | 13,011,415 | 8,636,948 | 8,138,164 |
| operating income | -4,251,000 | -27,928,000 | 4,050,000 | 5,079,000 | 5,012,000 | -5,471,000 | -5,658,000 | -9,640,000 | -21,157,000 | -31,522,000 | -22,832,000 | -21,536,000 | -3,971,000 | -24,516,000 | -15,171,000 | -11,814,000 | -8,810,000 | -4,284,000 | -3,032,000 | -3,901,000 | -645,000 | 1,036,000 | 2,612,602 | 4,429,221 | 607,621 |
| yoy | -184.82% | 410.47% | -171.58% | -152.69% | -123.69% | -82.64% | -75.22% | -55.24% | 432.79% | 28.58% | 50.50% | 82.29% | -54.93% | 472.27% | 400.36% | 202.85% | 1265.89% | -513.51% | -216.05% | -188.07% | -206.15% | ||||
| qoq | -84.78% | -789.58% | -20.26% | 1.34% | -191.61% | -3.31% | -41.31% | -54.44% | -32.88% | 38.06% | 6.02% | 442.33% | -83.80% | 61.60% | 28.42% | 34.10% | 105.65% | 41.29% | -22.28% | 504.81% | -162.26% | -60.35% | -41.01% | 628.94% | |
| operating margin % | -4.93% | -31.74% | 4.69% | 5.92% | 5.76% | -7.50% | -8.56% | -15.68% | -42.20% | -74.99% | -59.55% | -58.19% | -11.40% | -91.30% | -60.59% | -50.33% | -38.71% | -18.78% | -17.53% | -25.64% | -5.07% | 5.95% | 14.82% | 29.98% | 5.66% |
| interest income | 2,944,000 | 3,099,000 | 3,372,000 | 3,404,000 | 3,144,000 | 2,996,000 | 1,876,000 | 2,769,000 | 2,399,000 | 2,336,000 | 2,275,000 | 1,293,000 | 370,000 | 30,000 | 17,000 | 23,000 | 24,000 | 4,000 | 19,000 | 18,000 | 38,000 | 298,000 | 280,492 | 5,190 | 5,529 |
| changes in fair value of trading securities | 1,185,000 | -1,425,000 | |||||||||||||||||||||||
| interest expense | -21,000 | -17,000 | -92,000 | -201,000 | -270,000 | -14,000 | -2,000 | -2,000 | -3,000 | -4,000 | -4,000 | -6,000 | -4,000 | -3,000 | -395,000 | -706,000 | -769,000 | -764,000 | -765,888 | -1,088,130 | -1,692,582 | ||||
| income before income taxes | -143,000 | -26,271,000 | 7,885,000 | 8,282,000 | 7,886,000 | -2,489,000 | -2,541,000 | -6,873,000 | -18,761,000 | -29,190,000 | -20,561,000 | -20,249,000 | -3,605,000 | -24,489,000 | -15,155,000 | -11,791,000 | -8,786,000 | -4,280,000 | -4,805,000 | -4,589,000 | -1,376,000 | 570,000 | 2,126,767 | 5,849,295 | -1,269,079 |
| income tax benefit | -4,666,000 | 39,000 | 32,000 | 16,000 | |||||||||||||||||||||
| net income | 4,523,000 | -25,848,000 | 9,590,000 | 2,269,000 | 8,920,000 | -2,534,000 | -2,580,000 | -6,905,000 | -18,777,000 | -29,204,000 | -20,618,000 | -20,249,000 | -1,648,000 | -24,623,000 | -6,430,000 | -11,791,000 | -8,791,000 | -4,280,000 | -4,889,000 | -4,589,000 | -1,376,000 | 570,000 | 2,054,767 | 5,849,295 | -1,269,079 |
| yoy | -49.29% | 920.05% | -471.71% | -132.86% | -147.50% | -91.32% | -87.49% | -65.90% | 1039.38% | 18.60% | 220.65% | 71.73% | -81.25% | 475.30% | 31.52% | 156.94% | 538.88% | -850.88% | -337.93% | -178.45% | 8.43% | ||||
| qoq | -117.50% | -369.53% | 322.65% | -74.56% | -452.01% | -1.78% | -62.64% | -63.23% | -35.70% | 41.64% | 1.82% | 1128.70% | -93.31% | 282.94% | -45.47% | 34.13% | 105.40% | -12.46% | 6.54% | 233.50% | -341.40% | -72.26% | -64.87% | -560.91% | |
| net income margin % | 5.25% | -29.38% | 11.11% | 2.65% | 10.25% | -3.47% | -3.90% | -11.23% | -37.45% | -69.47% | -53.78% | -54.71% | -4.73% | -91.70% | -25.68% | -50.23% | -38.63% | -18.76% | -28.26% | -30.16% | -10.82% | 3.27% | 11.65% | 39.59% | -11.82% |
| earnings per share: | |||||||||||||||||||||||||
| basic | 0.16 | 0.35 | 0.08 | 0.32 | -0.17 | -0.25 | -0.23 | 0.03 | 0.18 | 0.43 | |||||||||||||||
| diluted | 0.15 | 0.32 | 0.08 | 0.31 | -0.17 | -0.25 | -0.23 | 0.03 | 0.46 | 0.05 | |||||||||||||||
| weighted-average shares outstanding: | |||||||||||||||||||||||||
| basic | 28,914 | 27,776 | 27,840 | 27,646 | 25,137 | 25,287 | 25,091 | 24,912 | 18,929 | 19,936 | 17,544 | 17,372 | 8,584 | 12,757,658 | |||||||||||
| diluted | 29,545 | 29,255 | 29,401 | 28,738 | 25,137 | 25,287 | 25,091 | 24,912 | 18,929 | 19,936 | 17,544 | 18,734 | 8,658 | 14,301,663 | |||||||||||
| income tax (benefit) expense | -423,000 | -1,034,000 | -455,750 | -1,957,000 | |||||||||||||||||||||
| loss per share, basic and diluted | -0.9 | -0.09 | -0.09 | -0.26 | -0.7 | -1.1 | -0.79 | -0.77 | -0.06 | -0.97 | |||||||||||||||
| weighted-average shares outstanding, basic and diluted | 28,609 | 27,485 | 26,802 | 26,834 | 26,733 | 26,607 | 26,054 | 26,316 | 26,064 | 25,424 | 2,152,965 | ||||||||||||||
| income tax expense | 1,256,000 | 6,013,000 | 45,000 | 14,000 | 134,000 | 1,250 | 5,000 | ||||||||||||||||||
| operating expenses and other operating income | |||||||||||||||||||||||||
| change in fair value of contingent consideration | -300,000 | -151,000 | -20,398,000 | 2,562,000 | |||||||||||||||||||||
| amortization of acquired intangible asset | 237,500 | 694,000 | 256,000 | ||||||||||||||||||||||
| other operating income | 1,882,000 | -1,882,000 | |||||||||||||||||||||||
| loss per share: | |||||||||||||||||||||||||
| basic | -0.248 | -0.47 | -0.35 | ||||||||||||||||||||||
| diluted | -0.248 | -0.47 | -0.35 | ||||||||||||||||||||||
| gross margin | 19,785,000 | 14,626,000 | 12,742,000 | 10,569,000 | 15,027,000 | 15,624,017 | 13,066,169 | 8,745,785 | |||||||||||||||||
| gain on extinguishment of debt | -431 | 5,213,431 | |||||||||||||||||||||||
| other income | -8 | -2,710,417 | -189,647 | ||||||||||||||||||||||
| convertible preferred stock cumulative dividends | -358 | 288,891 | 938,892 | ||||||||||||||||||||||
| accretion of redeemable convertible preferred stock to redemption value | -151 | 17,578 | 56,775 | ||||||||||||||||||||||
| net income and comprehensive income attributable to common stockholders | -4,889,000 | -4,589,000 | 570,000 | 2,055,276 | 5,542,826 | ||||||||||||||||||||
| earnings per share attributable to common stockholders: | |||||||||||||||||||||||||
| basic | 0.16 | 0.35 | 0.08 | 0.32 | -0.17 | -0.25 | -0.23 | 0.03 | 0.18 | 0.43 | |||||||||||||||
| diluted | 0.15 | 0.32 | 0.08 | 0.31 | -0.17 | -0.25 | -0.23 | 0.03 | 0.46 | 0.05 | |||||||||||||||
| loss per share attributable to common stockholders: | |||||||||||||||||||||||||
| basic | -0.08 | ||||||||||||||||||||||||
| diluted | -0.08 | ||||||||||||||||||||||||
| loss per share attributable to common stockholders, basic and diluted | -1.05 |
We provide you with 20 years income statements for Castle Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Castle Biosciences stock. Explore the full financial landscape of Castle Biosciences stock with our expertly curated income statements.
The information provided in this report about Castle Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.